Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.30 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.30 |
| ▸ | KLK7 | P49862 | 1/20 | 0.30 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24189621 | 0.85 | ALPL (0.34) | MAPTKMT2A | |
| SCHEMBL30396858 | 0.85 | ALPL (0.34) | MAPTKMT2A | |
| SCHEMBL29015360 | 0.85 | ALPL (0.34) | MAPTKMT2A | |
| SCHEMBL30395299 | 0.84 | ALDH1A1 (0.31) | ALDH1A1MAPT | |
| SCHEMBL30397150 | 0.84 | ALDH1A1 (0.31) | ALDH1A1MAPT | |
| SCHEMBL29015399 | 0.84 | ALDH1A1 (0.31) | ALDH1A1MAPT | |
| SCHEMBL26372679 | 0.84 | GABRA1 (0.42) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL18990257 | 0.83 | POLB (0.34) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL30267904 | 0.83 | POLB (0.34) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL18990256 | 0.83 | POLB (0.34) | KDM4EALDH1A1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-04-19 | — | — | US | disclosed |
| US-20220008386-A1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-01-13 | — | — | US | disclosed |
| EP-3596064-B1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11304929-B2 | Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors | PHGDH, G6PD, PHPT1 | KDM4E 2891/4885ALDH1A1 168/4885LMNA 2204/4885 |
| US-20220008386-A1 | TOSYLACETATE BASED COMPOUNDS AND DERIVATIVES THEREOF AS PHGDH INHIBITORS | PHGDH, G6PD, PHPT1 | KDM4E 2891/4885ALDH1A1 168/4885LMNA 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.